If you displayed patience with Cardinal Health's shares (CAH), first discussed here on April 21, 2009, at a pre-spin-off price of $34.22, over the past three months, you've been rewarded. Cardinal has soared past $40 resistance, after meandering in the low $30s for about nine months.

Cardinal probably will post a 3% to 5% 2011 revenue rise, after a 1.4% dip in 2010.

Key operation factors working in Cardinal's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls. Cardinal's medical unit, however, will lag other divisions, due to soft hospital markets.

Cardinal Health's shares (CAH), first discussed here on April 27, 2009, at a pre-spin-off price of $34.22, continued to meander over the past four months, but I still like the business model at this juncture. Here's why.

Cardinal probably will post a 3% to 5% 2010 revenue rise, followed by a 2% to 4% increase in 2011.

Key operation factors working in CAH's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls. Cardinal's medical unit, however, will lag other divisions, due to soft hospital markets.

Analyst Upgrades

• JPMorgan upgraded Vivus (VVUS) to overweight from neutral.
• Citigroup upgraded Corn Products (CPO) to buy from hold.
• Maxim Integrated (MXIM) was upgraded to outperform from market perform at FBR Capital.
• Cardinal Health (CAH) was upgraded to outperform from neutral at RW Baird.
• Citigroup upgraded Monster Worldwide (MWW) and EchoStar (SATS) to buy from hold, as well as Las Vegas Sands (LVS) to buy from sell.
• BMO Capital upgraded Potash (POT) and Barrick Gold (ABX) to outperform from market perform.

Analyst Upgrades

• Amazon.com (AMZN) was upgraded to buy from neutral at BofA/Merrill.
• Netflix (NFLX) was upgraded to outperform from perform at Oppenheimer and to neutral from sell at Janney Montgomery.
• Janney Montgomery also upgraded BJ's Wholesale (BJ) to buy from neutral.
• RW Baird upgraded Kforce.com (KFRC), SFN Group (SFN) and Young Innovations (YDNT) to outperform from neutral.
• NetSuite (N) was upgraded to neutral from underweight and Select Comfort (SCSS) was upgraded to overweight from neutral at Piper Jaffray.
• Flushing Financial (FFIC) was upgraded to outperform from market perform at Keefe Bruyette.
• National Instruments (NATI) was upgraded to buy from hold at Stifel Nicolaus.
• RBC Capital upgraded MDS Inc. (MDZ) to outperform from sector perform.

The shares of Cardinal Health (CAH) have meandered the past three months, but investors should view that sideways action as an extended opportunity to scoop-up shares, as the pleasant story continues with CAH.

Cardinal Health spun-off 81% of its clinical and medical products segment, CareFusion Corp. (CFN) in August 2009.

First discussed here on April 17, 2009 at a pre-spin-off price of $34.22, Cardinal's outlook is promising, due to a likely 3-5% 2010 revenue rise, after a 2.9% increase in 2009.

Key operation factors working in CAH's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls.

Analyst Upgrades

• Baird upgraded Dell (DELL) to outperform from neutral, citing valuation and improving IT hardware trends. The firm raised its target to $21 from $17.
• Janney Montgomery upgraded Regal Entertainment (RGC) to buy from neutral, citing box office momentum and improving potential for a dividend increase. The firm raised its target for shares to $20.50 from $16.
• Thomas Weisel upgraded CF Industries (CF) to overweight from market weight as it sees reduced financing risk following the equity offering and valuation.
• GameStop (GME) was upgraded to buy from hold at BB&T.
• Exxon Mobil (XOM) was upgraded to outperform from market perform at Raymond James.
• Cameron (CAM) was raised to outperform from market perform at BMO Capital.

The positive story continues with Cardinal Health (CAH), which spun-off 81% of its clinical and medical products segment, CareFusion Corp. (CFN), in August 2009.

I first discussed Cardinal Health as a potential buy at a pre-spin-off price of $34.22, Cardinal's stock has since returned to the $35-range, on a likely 3% to 5% 2010 revenue rise.

Key operational factors working in CAH's favor include increased prescription sales, modest price power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls.

Analyst Upgrades

• Goldman upgraded Walmart (WMT) to buy from neutral, citing compelling valuation, margin expansion and expense control. The firm has a $60 target on the stock.
• FBR Capital upgraded Urban Outfitters (URBN) to outperform from market perform on valuation and its belief that sustainable positive comp trends will return in 2010. The firm maintains a $35 price target on shares.
• JPMorgan upgraded Manpower (MAN) to overweight from neutral. The firm cites valuation and improving temp fundamentals in the U.S. and France for the upgrade and has a $70 price target on the stock.
• Arena Resources (ARD) was upgraded to buy from neutral at SunTrust.
• C.R. Bard (BCR) was upgraded to neutral from underweight at Piper Jaffray.
• Cardinal Health (CAH) was upgraded to overweight from market weight at Thomas Weisel.

Cardinal Health (CAH) spun-off 81% its clinical and medical products segment, CareFusion Corp. (CFN) in August 2009, hence an asset-adjusted CAH review is in order.

Look for CAH's 2010 revenue to increase 3.5-5%, boosted by increased prescription sales, lower customer attrition, and better performance of wider-margin generic drugs.

Analyst upgrades:

• FBR Capital upgraded AutoZone (NYSE: AZO) to Market Perform from Underperform on valuation following the company's Q4 results but lowered its target on shares to $134 from $137.
• Citigroup upgraded Calpine (NYSE: CPN) to Buy from Hold on valuation following Wednesday's sell-off. The firm believes Harbinger's share sale reflects an issue with the shareholders, not with the company, and raised its price target on the stock to $16.50 from $13.
• Credit Suisse upgraded Knight Transportation (NYSE: KNX) to Neutral from Underperform and raised its target to $17 from $16 based on valuation and the improved freight environment.
• Citrix Systems (NASDAQ: CTXS) was upgraded to Conviction Buy from Buy at Goldman.
• Webster Financial (NYSE: WBS) was upgraded to Outperform from Sector Perform at RBC Capital.
• Dr. Reddy's Labs (NYSE: RDY) was upgraded to Overweight from Equal Weight at Morgan Stanley.

Analyst upgrades:

• Wells Fargo transferred coverage of Cooper Industries (NYSE: CBE) with an Outperform rating, upgraded from the previous analysts' Market Perform rating. The firm believes commercial construction will be of less of a headwind for the company than the Street thinks, and has a $38-$41 valuation range on the stock.
• Kaufman Bros. upgraded SuccessFactors (NASDAQ: SFSF) to Buy from Hold after channel checks indicated demand trends picked up in July. The firm raised its target on shares to $15 from $12.
• UBS upgraded eBay (NASDAQ: EBAY) to Buy from Neutral and believes Marketplace transaction growth is "turning the corner." Additionally, the firm believes the secondary market represents a long-term opportunity for the company. The firm raised its target to $28 from $24.
• Novartis (NYSE: NVS) was upgraded to Buy from Hold at Jefferies.
• Arcelor Mittal (NYSE: MT) was upgraded to Buy from Hold at Citigroup.
• Cardinal Health (NYSE: CAH) was upgraded to Buy from Neutral at Goldman.
• Yahoo! (NASDAQ: YHOO) was upgraded to Outperform from Market Perform AMC Monday at Bernstein.

Analyst upgrades:

• Citigroup upgraded Talbots (NYSE: TLB) to Buy from Hold on expectations the company's sales and margins are at an inflection point. The firm expects comps to turn positive in the next six months and raised its target on shares to $9.50 from $5.
• JMP Securities believes that Apple's (NASDAQ: AAPL) incoming iPod product cycle, geographic expansion of iPhones, and market expansion led by new products will result in "significant" outperformance. The firm upgraded shares to Outperform from Market Perform and has a $200 target on the stock.
• Credit Suisse upgraded Tiffany (NYSE: TIF) to Outperform from Neutral citing productivity comps and gross margin upside, leading to potential upside to 2010 Street estimates. The firm raised its target to $45 from $20.
• Brady (NYSE: BRC) was upgraded to Buy from Hold at KeyBanc.
• Time Warner (NYSE: TWX) was upgraded to Conviction Buy from Neutral at Goldman.
• RadioShack (NYSE: RSH) was upgraded to Overweight from Equal Weight at Morgan Stanley.

It's a difficult call, but I'm Reiterating my Buy rating for Cardinal Health (NYSE: CAH), first recommended on April 21, 2009 at a price of $33.52.

Cardinal Health has meandered since April, despite generally favorable investor reviews of CAH's plan to spin-off its clinical medical products segment in mid-2009, to be called CareFusion Corp., allowing Cardinal to focus on revitalizing its health care supply chain services business, which recently returned to profitability.

Analyst upgrades:

• Keefe Bruyette upgraded BB&T (NYSE: BBT) to Market Perform from Underperform as it believes downside risk has been reduced following the company's capital raise. The firm raised its target price to $23 from $15.
  
• Janney Montgomery upgraded FEI Company (NASDAQ: FEIC) to Buy from Neutral on expectations margins will improve and various country stimulus packages will provide benefits in 2010. The firm has a $31 target on the stock.
  
• Citigroup upgraded Tyco Electronics (NYSE: TEL) to Buy from Hold as it believes automotive headwinds are priced in and the company's long-term fundamentals are intact. The firm raised its target price to $25 from $19.
• Barrick Gold (NYSE: ABX) was upgraded to Outperform from Sector Perform at RBC Capital.
  
• J.B. Hunt (NYSE: JBHT) was raised to Overweight from Equal Weight at Stephens.
  
• Roper Industries (NYSE: ROP) was upgraded at Oppenheimer to Outperform from Perform.

Analyst upgrades:

• Morgan Stanley upgraded Chesapeake Energy (NYSE: CHK) to Overweight from Equal Weight as they expect the company to benefit from higher natural gas prices in 2010. The firm has a $34 target on shares.
• Citigroup upgraded Energy Conversion (NASDAQ: ENER) to Hold from Sell on valuation is it finds the risk/reward balanced at current levels. The firm raised its target price to $16 from $13.
• Jefferies upgraded Lifetime Brands (NASDAQ: LCUT) to Buy from Underperform to reflect reduced liquidity concerns and an improved outlook for Global Direct Sellers. The firm raised its target price to $4 from $2.
• American Eagle (NYSE: AEO) was upgraded to Overweight from Equal Weight at Barclays.
• TJX Companies (NYSE: TJX) was upgraded at Barclays to Overweight from Equal Weight and to Outperform from Netural at Credit Suisse.
• STEC Inc (NASDAQ: STEC) was raised to Overweight from Market Weight at Thomas Weisel.